P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in PTS With Malignant Mesothelioma
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1264
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV